Wall Street analysts forecast that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will post ($1.33) earnings per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Adamas Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.21) and the lowest estimate coming in at ($1.47). Adamas Pharmaceuticals reported earnings of ($1.04) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 27.9%. The business is expected to announce its next earnings results on Thursday, November 1st.
On average, analysts expect that Adamas Pharmaceuticals will report full-year earnings of ($5.37) per share for the current financial year, with EPS estimates ranging from ($5.61) to ($4.95). For the next financial year, analysts anticipate that the firm will report earnings of ($3.76) per share, with EPS estimates ranging from ($4.17) to ($3.04). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($1.26) EPS for the quarter, beating the consensus estimate of ($1.41) by $0.15. Adamas Pharmaceuticals had a negative return on equity of 104.86% and a negative net margin of 1,138.59%. The firm had revenue of $7.57 million for the quarter, compared to analyst estimates of $4.84 million.
In related news, COO Richard King sold 2,501 shares of Adamas Pharmaceuticals stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $25.48, for a total transaction of $63,725.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jennifer J. Rhodes sold 1,002 shares of Adamas Pharmaceuticals stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $25.48, for a total value of $25,530.96. The disclosure for this sale can be found here. 24.60% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in ADMS. BlackRock Inc. lifted its holdings in shares of Adamas Pharmaceuticals by 24.3% during the second quarter. BlackRock Inc. now owns 1,846,096 shares of the specialty pharmaceutical company’s stock worth $47,684,000 after purchasing an additional 361,303 shares during the period. Millennium Management LLC lifted its holdings in shares of Adamas Pharmaceuticals by 318.2% during the second quarter. Millennium Management LLC now owns 342,180 shares of the specialty pharmaceutical company’s stock worth $8,839,000 after purchasing an additional 260,360 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of Adamas Pharmaceuticals by 11.6% during the second quarter. Point72 Asset Management L.P. now owns 2,272,115 shares of the specialty pharmaceutical company’s stock worth $58,689,000 after purchasing an additional 235,515 shares during the period. Sphera Funds Management LTD. lifted its holdings in shares of Adamas Pharmaceuticals by 138.8% during the first quarter. Sphera Funds Management LTD. now owns 335,500 shares of the specialty pharmaceutical company’s stock worth $8,018,000 after purchasing an additional 195,000 shares during the period. Finally, Kornitzer Capital Management Inc. KS acquired a new stake in shares of Adamas Pharmaceuticals during the first quarter worth about $4,191,000. 92.32% of the stock is owned by hedge funds and other institutional investors.
ADMS stock traded up $0.64 during trading on Thursday, reaching $22.84. 391,200 shares of the company traded hands, compared to its average volume of 801,778. Adamas Pharmaceuticals has a 12 month low of $13.68 and a 12 month high of $44.00. The company has a market cap of $628.10 million, a P/E ratio of -5.75 and a beta of 1.42. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.92 and a quick ratio of 9.74.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Featured Article: How to Invest in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.